Skip to main content
OpenTrials
Completed

NCT Number: NCT02365532

Effect of Oral GS-6615 on Dofetilide-Induced QT Prolongation, Safety, and Tolerability in Healthy Adults

This study will evaluate the effect of oral GS-6615 on QTc interval in healthy adults with dofetilide-induced QTc prolongation.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–40 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Spaulding Clinical Research, LLC

West Bend, Wisconsin, 53095, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Must, in the opinion of the investigator, be in good health based upon medical history and physical examination, including vital signs
  • Have a calculated body mass index (BMI) from 18 to 30 kg/m^2, inclusive, at study screening
  • Have either a normal 12-lead electrocardiogram (ECG) or one with abnormalities that are considered clinically insignificant and which do not interfere with the ability to interpret the QT interval in the opinion of the investigator in consultation with the medical monitor

Exclusion criteria

  • History of meningitis or encephalitis, epilepsy, seizures (known or suspected), migraines, tremors, myoclonic jerks, sleep disorder, anxiety, syncope, head injuries, or a family history of seizures
  • Have any serious or active medical or psychiatric illness (including depression) which, in the opinion of the investigator, would interfere with treatment, assessment, or compliance with the protocol. This would include renal, cardiac, hematological, hepatic, pulmonary (including chronic asthma), endocrine (including diabetes), central nervous, gastrointestinal (including an ulcer), vascular, metabolic (thyroid disorders, adrenal disease), immunodeficiency disorders, active infection, or malignancy that are clinically significant or requiring treatment.
  • Presence or history of cardiovascular disease, including structural heart disease, myocardial infarction (by ECG and/or clinical history), history of ventricular tachycardia or torsade de pointes, heart failure or cardiomyopathy (by clinical history and/or left ventricular ejection fraction < 40%), presence of cardiac conduction abnormalities, a family history of Long QT or Brugada Syndrome, or unexplained death in an otherwise healthy individual between the ages of 1 and 30 years
  • Additional cardiovascular-specific exclusion criteria include findings on screening ECG of:
  • QTcF interval > 430 msec
  • PR interval > 220 msec
  • QRS duration > 110 msec
  • Second- or third-degree atrioventricular block
  • Complete left or right bundle branch block or incomplete right bundle branch block
  • Resting heart rate < 40 or > 100 beats per minute (bpm)
  • Pathological Q waves (defined as Q wave > 40 msec)
  • Ventricular pre-excitation
  • More than 2 ectopic beats
  • Syncope, palpitations, or unexplained dizziness

Treatment and study plan

GS-6615

Drug

GS-6615 tablets administered orally

Placebo to match GS-6615

Drug

Placebo to match GS-6615 tablets administered orally

Placebo to match dofetilide

Drug

Placebo to match dofetilide capsules administered orally

Dofetilide

Drug

Dofetilide 500 μg capsules administered orally according to the current prescribing information

Primary outcomes

  1. Change in daytime QT interval corrected for heart rate using the Fridericia formula (QTcF)

    Time frame: Up to 6 days

  2. Pharmacokinetic (PK) profiles of GS-6615 and dofetilide

    Time frame: Predose and postdose on Days -2 through Day 4

    This endpoint will measure the plasma PK profiles of GS-6615 and dofetilide. PK parameters that will be measured include Cmax, Tmax, AUC_0-24, and AUC_0-tlast.

Secondary outcomes

  1. Incidence of adverse events, clinical laboratory test results, vital sign measurements, and electrocardiogram (ECG) data

    Time frame: Up to 6 days

    This endpoint will measure the safety and tolerability profile of GS-6615.

Sponsors and collaborators

Lead sponsor

Gilead Sciences

Industry

Registry information

Official study title

A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Oral GS-6615 on Dofetilide-Induced QT Prolongation, Safety, and Tolerability in Healthy Subjects

Important dates

Study start
2015
Primary completion
2015
Study completion
2015
First posted
Feb 19, 2015
Registry last updated
May 20, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.